Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.

Abstract: Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample.

Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

Abstract: The invention concerns a method for obtaining an antiserum directed against a proteinic toxin by administering to an animal a solution comprising a genetic construct encoding a toxin immunogenic fragment, then applying an electric field in the administering zone, and isolating the serum. The invention also concerns the antiserum obtainable by the method as well as the use of the solution for making a medicine for preventing or treating a toxic effect related to absorption by a mammal of a toxin. The invention is characterized in that said medicine is formulated to be administered by electrotransfer.

Abstract: The invention relates to a complex formed between the 3?-phosphoadenosine 5?-phosphate and polypeptide in human cells, to the use of pAp or of a molecule which mimics pAp for modulating the activity of poly(ADP-ribose)polymerase and small fragment nuclease in human cells, and to process of screening a molecule as a candidate drug for the treatment of diseases where modulation of at least one of the metabolic activities modulated by pAp is needed such as bipolar disorder or related diseases.

Abstract: The present invention provides the crystal structure of the Trypanosoma cruzi PRACA proline racemase. Methods of modelling drugs that treat or prevent infection by T. cruzi are also provided, as are the drugs that are identified.

Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr; B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.

Abstract: DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.

Abstract: Methods for identifying molecules which inhibit the virulence or pathogenicity of Helicobacter pylori by modulating the activity of hydrolases encoded by genes amiA, mltD and slt. Compositions and diagnostic and treatment methods using hydrolases and molecules which inhibit them.

Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.

Abstract: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

Abstract: The present invention relates to peptides and polypeptide derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls: X-His-Asn-Pro-Y in which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.

Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Abstract: The present invention relates to recombinant negative strand RNA molecules which may be used to express heterologous proteins in animal cells and/or to construct recombinant viruses able to express heterologous proteins during their multiplication in host animal cells.

Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.

Abstract: A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.

Abstract: The present invention relates to recombinant negative strand RNA molecules which may be used to express heterologous proteins in animal cells and/or to construct recombinant viruses able to express heterologous proteins during their multiplication in host animal cells.

Abstract: The present invention relates to pro-apoptotic fragments of the Dengue virus pRM and E glycoproteins, methods of screening for molecules capable of inducing apoptosis and methods of inducing apoptosis in a cell.

Abstract: The invention relates to an isolated immune complex comprising a protein and an antibody that binds with said protein, wherein the protein is selected from the group consisting of gp80 of HIV-2 and gp65 of SIV, wherein said gp80 is a glycoprotein having an apparent molecular weight of 80 kDa, as determined by SDS-PAGE, and further wherein said gp65 is a glycoprotein having an apparent molecular weight of 65 kDa as determined by SDS-PAGE. Also provided are an immunogenic composition comprising an amount of gp80 protein of human immunodeficiency virus type 2 (HIV-2) sufficient to induce an immune response and a pharmaceutically acceptible carrier, and a composition comprising at least one antigen selected from the group consisting of gp80 protein of HIV-2 and gp65SIV.

Abstract: The invention concerns human papillomavirus (HPV) DNA and more particularly the probes derived from these papillomaviruses, as well as the methods of detecting HPV using these probes. These human papillomaviruses are designated as HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4.